GlassScriptPhysician profile
Farid Ud Din
NPI 1609115872
$2,484.87
in general payments reported to CMS, 2019-2025
32 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $217 · 2021: $103 · 2022: $153 · 2023: $350 · 2024: $800 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $281.42 | 2021-2025 | Briviact, Fintepla |
| Supernus Pharmaceuticals, INC. | $258.12 | 2023-2025 | Qelbree, Qelbree |
| Sumitomo Pharma America, INC. | $213.38 | 2023-2024 | Aptiom |
| Jazz Pharmaceuticals INC. | $204.02 | 2024-2025 | |
| Neurelis, INC. | $198.00 | 2022-2025 | Valtoco |
| Abbvie INC. | $192.47 | 2023-2025 | Botox |
| Mdd US Operations, LLC | $181.46 | 2020 | |
| Lundbeck LLC | $175.45 | 2022-2025 | Vyepti |
| Eisai INC. | $148.76 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $60.32 | 2024 | Xeomin |
| Sk Life Science, INC. | $54.18 | 2022-2025 | |
| Ge Healthcare | $48.69 | 2023-2024 | |
| Biogen, INC. | $41.94 | 2024-2025 | Skyclarys |
| Collegium Pharmaceutical, INC. | $41.79 | 2025 | Jornay Pm |
| Neuronetics, INC. | $35.58 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $32.06 | 2021 | |
| Axsome Therapeutics, INC. | $31.96 | 2025 | Symbravo |
| Aquestive Therapeutics, INC. | $30.80 | 2019 | |
| Corium, LLC | $26.93 | 2025 | Azstarys |
| Aprecia Pharmaceuticals, LLC | $25.82 | 2021 | |
| Sanofi Pasteur INC. | $21.65 | 2022 | |
| Tris Pharma INC | $19.37 | 2019 | |
| Biomarin Pharmaceutical INC. | $18.07 | 2019 | |
| Averitas Pharma INC. | $17.79 | 2023 | Qutenza |
| Ns Pharma, INC. | $17.60 | 2024 | Viltepso |
| Life Molecular Imaging LTD | $16.73 | 2023 | Neuraceq |
| Arbor Pharmaceuticals, INC. | $16.51 | 2019 | |
| Cranial Technologies, INC | $16.50 | 2021 | |
| Boston Scientific Corporation | $16.22 | 2025 | Wavewriter Alpha Prime 16 |
| Acadia Pharmaceuticals INC | $15.19 | 2023 | Daybue |
| Shire North American Group INC | $13.48 | 2019 | |
| Genentech USA, INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farid Din listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.